In this sense, several AD therapies have focused on amyloid-β targeted treatments, but recent studies have demonstrated that tau pathway is connected with clinical expansion of AD signs, indicating that can be a possible therapeutic target. This evidence concerns the gene MAPT and Alzheimer disease.